CardioGenics announces clinical test sites for QL Care portable blood analyzer CardioGenics Holdings Inc. Troponin-I, a protein marker released into the bloodstream by dying heart cells, definitively confirms that a heart attack is happening . Related StoriesAmputation is not wound healingVISERA 4K UHD endoscopy program gives surgeons 4x resolutionGenetic carrier screening: an interview with Don Hardison, CEO of Good Begin GeneticsThe outcomes will be compared. The head-to-head confirmation lab tests will commence during Q3, upon acceptance of the Institutional Review Boards, and take 45 times to complete approximately.


Quality control and the capability to develop standardized products will be the essential keys to continue with both medical marijuana under condition laws, as well as being the foundation of any pharmaceutical formulations we will submit for FDA clinical trials.’ Richard Cowan, Cannabis Science CFO, explained, ‘The revenue potential out of this facility is actually very significant, and we shall make open public our estimates on the projected revenue soon, but, much like our announced acquisitions in Colorado and Montana previously, our main focus will stay on R&D. As Dr. Melamede offers pointed out, previously new biotech companies haven’t known whether their proposed products were safe and effective until they were submitted for FDA medical trials.